Niagen Bioscience said Evotec will support preclinical strategy and data generation for NB4168, aiming to move the rare-disease asset toward future clinical mil

Niagen Bioscience said Evotec will support preclinical strategy and data generation for NB4168, aiming to move the rare-disease asset toward future clinical milestones. NB4168 already holds FDA Rare Pediatric Disease and EMA Orphan designations.